
## **Giorgio Gentile**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7784385/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Day-Night Dip and Early-Morning Surge in Blood Pressure in Hypertension. Hypertension, 2012, 60, 34-42.	2.7	264
2	Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. Journal of Hypertension, 2011, 29, 1253-1269.	0.5	235
3	Prevalence and Correlates of Self-Reported Sexual Dysfunction in CKD: A Meta-analysis of Observational Studies. American Journal of Kidney Diseases, 2010, 56, 670-685.	1.9	155
4	Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. Journal of Hypertension, 2008, 26, 1282-1289.	0.5	121
5	Prevalence and severity of oral disease in adults with chronic kidney disease: a systematic review of observational studies. Nephrology Dialysis Transplantation, 2014, 29, 364-375.	0.7	106
6	Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrology Dialysis Transplantation, 2011, 26, 2827-2847.	0.7	94
7	Sexual Dysfunction in Women with ESRD Requiring Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 974-981.	4.5	82
8	Why Is Out-of-Office Blood Pressure Measurement Needed?. Hypertension, 2009, 54, 181-187.	2.7	77
9	The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vascular Health and Risk Management, 2008, Volume 4, 971-981.	2.3	76
10	More Versus Less Intensive Blood Pressure–Lowering Strategy. Hypertension, 2016, 68, 642-653.	2.7	75
11	Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. Journal of Hypertension, 2010, 28, 1356-1365.	0.5	69
12	Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis. European Heart Journal, 2008, 30, 679-688.	2.2	66
13	Home Blood Pressure Measurements Will Not Replace 24-Hour Ambulatory Blood Pressure Monitoring. Hypertension, 2009, 54, 188-195.	2.7	56
14	Are Diabetes, Hypertension, and Obesity Independent Risk Factors for Endometrial Polyps?. Journal of Minimally Invasive Gynecology, 2009, 16, 157-162.	0.6	49
15	An independent prognostic factor for the development of endometrial polyps in infertile patients. Fertility and Sterility, 2009, 91, e7-e7.	1.0	46
16	The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. Journal of Hypertension, 2009, 27, 1697-1704.	0.5	44
17	Prevalence and correlates of erectile dysfunction in men on chronic haemodialysis: a multinational cross-sectional study. Nephrology Dialysis Transplantation, 2012, 27, 2479-2488.	0.7	44
18	Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vascular Health and Risk Management, 2009, 5, 411.	2.3	39

**GIORGIO GENTILE** 

#	Article	IF	CITATIONS
19	Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin–angiotensin system blockers. Therapeutic Advances in Cardiovascular Disease, 2012, 6, 81-91.	2.1	39
20	New-Onset Hyperglycemia and Acute Coronary Syndrome: A Systematic Overview and Meta-Analysis. Current Diabetes Reviews, 2010, 6, 102-110.	1.3	37
21	β-Blockers Reduce Mortality in Patients Undergoing High-Risk Non-Cardiac Surgery. American Journal of Cardiovascular Drugs, 2010, 10, 247-259.	2.2	36
22	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 785-794.	4.5	35
23	Blood Pressure, Proteinuria, and Phosphate as Risk Factors for Progressive Kidney Disease: A Hypothesis. American Journal of Kidney Diseases, 2013, 62, 984-992.	1.9	34
24	Novel Biomarkers for Renal Diseases? None for the Moment (but One). Journal of Biomolecular Screening, 2016, 21, 655-670.	2.6	33
25	Thiamine deficiency and beriberi features in a patient with hyperemesis gravidarum. Nutrition, 2005, 21, 967-968.	2.4	27
26	Is Kt/V useful in elderly dialysis patients? Pro and Con arguments. Nephrology Dialysis Transplantation, 2018, 33, 742-750.	0.7	26
27	Aliskiren versus ramipril in hypertension. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 193-200.	2.1	23
28	Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Review of Clinical Pharmacology, 2011, 4, 151-161.	3.1	21
29	Tight Blood Pressure Control in Diabetes: Evidence-Based Review of Treatment Targets in Patients with Diabetes. Current Cardiology Reports, 2012, 14, 89-96.	2.9	21
30	Dual Renin-Angiotensin System Blockade for Nephroprotection: Still under Scrutiny. Nephron, 2015, 129, 39-41.	1.8	20
31	European and US guidelines for arterial hypertension: similarities and differences. European Journal of Internal Medicine, 2019, 63, 3-8.	2.2	20
32	Estimated GFR reporting is not sufficient to allow detection of chronic kidney disease in an Italian regional hospital. BMC Nephrology, 2009, 10, 24.	1.8	16
33	Optimal Therapy in Hypertensive Subjects with Diabetes Mellitus. Current Atherosclerosis Reports, 2011, 13, 176-185.	4.8	16
34	Treatment strategies for osteoarthritis patients with pain and hypertension. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 229-240.	2.7	15
35	Novel effective drugs for diabetic kidney disease? or not?. Expert Opinion on Emerging Drugs, 2014, 19, 571-601.	2.4	15
36	Comparative assessment of angiotensin receptor blockers in different clinical settings. Vascular Health and Risk Management, 2009, 5, 939.	2.3	14

**GIORGIO GENTILE** 

#	Article	IF	CITATIONS
37	Blood pressure lowering in the oldest old. Journal of Hypertension, 2010, 28, 1373-1376.	0.5	13
38	The 2018 ESC/ESH hypertension guidelines: Should nephrologists always stop at the lower boundary?. Journal of Nephrology, 2018, 31, 621-626.	2.0	13
39	Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. Expert Review of Cardiovascular Therapy, 2009, 7, 1349-1361.	1.5	12
40	Managing end-stage renal disease in the elderly: state-of-the-art, challenges and opportunities. Aging Health, 2013, 9, 539-552.	0.3	12
41	Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 115-128.	3.3	10
42	Benefits of more intensive versus less intensive blood pressure control. Updated trial sequential analysis. European Journal of Internal Medicine, 2022, 101, 49-55.	2.2	9
43	β-blockers and risk of all-cause mortality in non-cardiac surgery. Therapeutic Advances in Cardiovascular Disease, 2010, 4, 109-118.	2.1	7
44	Blood pressure lowering in diabetic patients. Journal of Hypertension, 2012, 30, 438-439.	0.5	7
45	Role and prognostic value of individual ambulatory blood pressure components in chronic kidney disease. Journal of Human Hypertension, 2018, 32, 625-632.	2.2	6
46	The Quest to Standardize Hemodialysis Care. Contributions To Nephrology, 2011, 171, 39-49.	1.1	5
47	Pregabalin-induced urticarial rash and neutropenia in a renal transplant recipient: a case report. BMC Nephrology, 2019, 20, 207.	1.8	5
48	Response to Home Blood Pressure Measurements Will or Will Not Replace 24-Hour Ambulatory Blood Pressure Measurement. Hypertension, 2009, 54, .	2.7	4
49	Low-Dose RATG with or without Basiliximab in Renal Transplantation: A Matched-Cohort Observational Study. American Journal of Nephrology, 2015, 41, 16-27.	3.1	4
50	Should we shift toward higher blood pressure targets in patients with chronic kidney disease. Journal of Nephrology, 2011, 24, 673-685.	2.0	4
51	The emerging role of high-density lipoprotein cholesterol in hypertension trials. Journal of Hypertension, 2009, 27, 458-460.	0.5	3
52	Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab. BMJ Case Reports, 2021, 14, e238210.	0.5	3
53	Tight Blood Pressure Control in Chronic Kidney Disease. Journal of Cardiovascular Development and Disease, 2022, 9, 139.	1.6	3
54	Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and protection from stroke. Expert Review of Cardiovascular Therapy, 2008, 6, 1171-1174.	1.5	2

**GIORGIO GENTILE** 

#	Article	IF	CITATIONS
55	Clinical Significance of the Blood Pressure Changes from Day to Night. Current Hypertension Reviews, 2011, 7, 13-19.	0.9	2
56	Chronic kidney disease and risk of mortality, cardiovascular events or end-stage renal disease in older patients with hypertension. Expert Review of Cardiovascular Therapy, 2012, 10, 1213-1216.	1.5	2
57	Hair today, gone tomorrow: How personal protective equipment guidance changed doctor's facial hair during the COVID â€19 pandemic. Health Science Reports, 2021, 4, e278.	1.5	2
58	Glucose Lowering, Hypoglycemia, and Cardiovascular Disease Risk. Current Cardiovascular Risk Reports, 2010, 4, 159-164.	2.0	1
59	Emerging therapies in the management of hypertensive patients with osteoarthritis. Clinical Investigation, 2011, 1, 125-136.	0.0	1
60	Performance of creatinine- and cystatin C-based formulas to estimate glomerular filtration rate. European Journal of Internal Medicine, 2020, 80, 16-17.	2.2	1
61	Should we prefer different drugs to treat hypertension in older and younger adults? Practical implications of clinical trials: European perspective. , 2008, 118, 513-6.		1
62	Blood pressure lowering in the oldest old: a step toward abandoning arbitrary blood pressure targets. Journal of Hypertension, 2011, 29, 173-175.	0.5	0
63	Response to Is Vascular Morning Blood Pressure Surge in the Elderly Resistant to Antihypertensives and More Risky?. Hypertension, 2012, 60, .	2.7	0